希少疾病用医薬品の世界市場 2023-2027

当レポートでは、希少疾病用医薬品市場をモニターしており、2022年から2027年の間に1,708億米ドル、予測期間中のCAGRは14.02%で成長すると予測しています。

当レポートでは、希少疾病用医薬品市場について、全体的な分析、市場規模と予測、動向、成長促進要因・課題、さらに約25のベンダーを網羅したベンダー分析を行っています。

現在の市場シナリオ、最新動向と促進要因、市場全体の環境に関する最新の分析を提供しています。市場は、強力なパイプラインと最近の医薬品承認、希少疾患の発生率の増加、希少医薬品開発のためのインセンティブの利用可能性によって牽引されています。

本調査では、今後数年間の希少疾病用医薬品市場の成長を促進する主な理由の一つとして、アライアンス、パートナーシップ、M&Aへの戦略的注力を挙げています。また、併用療法や新規ターゲットの出現、遺伝子検査やタンパク質バイオマーカーの需要の高まりは、同市場の大きな需要につながると考えられます。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場別分析
• 市場規模 2022
• 市場の見通し 2022-2027

第4章 市場規模実績

• 希少疾病用医薬品の世界市場 2017-2021
• 分散型チャネルセグメント分析 2017-2021
• 製品セグメント分析 2017-2021
• 地域別分析 2017-2021
• 国別分析 2017-2021

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：流通チャネル別

• 市場セグメント
• 比較：流通チャネル別
• 病院薬局：市場規模と予測 2022-2027
• 専門薬局：市場規模と予測 2022-2027
• 小売薬局：市場規模と予測 2022-2027
• その他：市場規模と予測 2022-2027
• 市場機会：流通チャネル別

第7章 市場セグメンテーション：製品別

• 市場セグメント
• 比較：製品別
• 生物製剤：市場規模と予測 2022-2027
• 非生物製剤：市場規模と予測 2022-2027
• 市場機会：製品別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2022-2027
• 欧州：市場規模と予測 2022-2027
• アジア：市場規模と予測 2022-2027
• 世界のその他の地域：市場規模と予測 2022-2027
• 米国：市場規模と予測 2022-2027
• 英国：市場規模と予測 2022-2027
• カナダ：市場規模と予測 2022-2027
• 中国：市場規模と予測 2022-2027
• ドイツ：市場規模と予測 2022-2027
• 地域情勢別市場機会

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• AbbVie Inc.
• Alnylam Pharmaceuticals Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• bluebird bio Inc.
• Bristol Myers Squibb Co.
• CSL Ltd.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Ipsen Pharma
• Johnson and Johnson Services Inc.
• Merck and Co. Inc.
• Novartis AG
• Ractigen Therapeutics

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibits6: Executive Summary - Chart on Market Segmentation by Product
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits18: Historic Market Size - Data Table on Global orphan drugs market 2017 - 2021 ($ billion)
• Exhibits19: Historic Market Size - Distributed Channel Segment 2017 - 2021 ($ billion)
• Exhibits20: Historic Market Size - Product Segment 2017 - 2021 ($ billion)
• Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ billion)
• Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ billion)
• Exhibits23: Five forces analysis - Comparison between 2022 and 2027
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
• Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
• Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
• Exhibits29: Chart on Market condition - Five forces 2022 and 2027
• Exhibits30: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibits31: Data Table on Distribution Channel - Market share 2022-2027 (%)
• Exhibits32: Chart on Comparison by Distribution Channel
• Exhibits33: Data Table on Comparison by Distribution Channel
• Exhibits34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibits35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibits36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits38: Chart on Specialty pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibits39: Data Table on Specialty pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibits40: Chart on Specialty pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits41: Data Table on Specialty pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits42: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibits43: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibits44: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits45: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits46: Chart on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibits47: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibits48: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibits49: Data Table on Others - Year-over-year growth 2022-2027 (%)
• Exhibits50: Market opportunity by Distribution Channel ($ billion)
• Exhibits51: Data Table on Market opportunity by Distribution Channel ($ billion)
• Exhibits52: Chart on Product - Market share 2022-2027 (%)
• Exhibits53: Data Table on Product - Market share 2022-2027 (%)
• Exhibits54: Chart on Comparison by Product
• Exhibits55: Data Table on Comparison by Product
• Exhibits56: Chart on Biologics - Market size and forecast 2022-2027 ($ billion)
• Exhibits57: Data Table on Biologics - Market size and forecast 2022-2027 ($ billion)
• Exhibits58: Chart on Biologics - Year-over-year growth 2022-2027 (%)
• Exhibits59: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
• Exhibits60: Chart on Non-biologics - Market size and forecast 2022-2027 ($ billion)
• Exhibits61: Data Table on Non-biologics - Market size and forecast 2022-2027 ($ billion)
• Exhibits62: Chart on Non-biologics - Year-over-year growth 2022-2027 (%)
• Exhibits63: Data Table on Non-biologics - Year-over-year growth 2022-2027 (%)
• Exhibits64: Market opportunity by Product ($ billion)
• Exhibits65: Data Table on Market opportunity by Product ($ billion)
• Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits67: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits69: Chart on Geographic comparison
• Exhibits70: Data Table on Geographic comparison
• Exhibits71: Chart on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibits72: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibits73: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibits74: Data Table on North America - Year-over-year growth 2022-2027 (%)
• Exhibits75: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibits76: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibits77: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits79: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibits80: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibits81: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits87: Chart on US - Market size and forecast 2022-2027 ($ billion)
• Exhibits88: Data Table on US - Market size and forecast 2022-2027 ($ billion)
• Exhibits89: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibits90: Data Table on US - Year-over-year growth 2022-2027 (%)
• Exhibits91: Chart on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibits92: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibits93: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibits94: Data Table on UK - Year-over-year growth 2022-2027 (%)
• Exhibits95: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
• Exhibits96: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
• Exhibits97: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits99: Chart on China - Market size and forecast 2022-2027 ($ billion)
• Exhibits100: Data Table on China - Market size and forecast 2022-2027 ($ billion)
• Exhibits101: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibits102: Data Table on China - Year-over-year growth 2022-2027 (%)
• Exhibits103: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibits104: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibits105: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits106: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits107: Market opportunity By Geographical Landscape ($ billion)
• Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ billion)
• Exhibits109: Impact of drivers and challenges in 2022 and 2027
• Exhibits110: Overview on Criticality of inputs and Factors of differentiation
• Exhibits111: Overview on factors of disruption
• Exhibits112: Impact of key risks on business
• Exhibits113: Vendors covered
• Exhibits114: Matrix on vendor position and classification
• Exhibits115: AbbVie Inc. - Overview
• Exhibits116: AbbVie Inc. - Product / Service
• Exhibits117: AbbVie Inc. - Key news
• Exhibits118: AbbVie Inc. - Key offerings
• Exhibits119: Alnylam Pharmaceuticals Inc. - Overview
• Exhibits120: Alnylam Pharmaceuticals Inc. - Product / Service
• Exhibits121: Alnylam Pharmaceuticals Inc. - Key news
• Exhibits122: Alnylam Pharmaceuticals Inc. - Key offerings
• Exhibits123: Astellas Pharma Inc. - Overview
• Exhibits124: Astellas Pharma Inc. - Product / Service
• Exhibits125: Astellas Pharma Inc. - Key news
• Exhibits126: Astellas Pharma Inc. - Key offerings
• Exhibits127: AstraZeneca Plc - Overview
• Exhibits128: AstraZeneca Plc - Product / Service
• Exhibits129: AstraZeneca Plc - Key news
• Exhibits130: AstraZeneca Plc - Key offerings
• Exhibits131: bluebird bio Inc. - Overview
• Exhibits132: bluebird bio Inc. - Product / Service
• Exhibits133: bluebird bio Inc. - Key offerings
• Exhibits134: Bristol Myers Squibb Co. - Overview
• Exhibits135: Bristol Myers Squibb Co. - Product / Service
• Exhibits136: Bristol Myers Squibb Co. - Key news
• Exhibits137: Bristol Myers Squibb Co. - Key offerings
• Exhibits138: CSL Ltd. - Overview
• Exhibits139: CSL Ltd. - Business segments
• Exhibits140: CSL Ltd. - Key news
• Exhibits141: CSL Ltd. - Key offerings
• Exhibits142: CSL Ltd. - Segment focus
• Exhibits143: F. Hoffmann La Roche Ltd. - Overview
• Exhibits144: F. Hoffmann La Roche Ltd. - Business segments
• Exhibits145: F. Hoffmann La Roche Ltd. - Key news
• Exhibits146: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibits147: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibits148: Gilead Sciences Inc. - Overview
• Exhibits149: Gilead Sciences Inc. - Product / Service
• Exhibits150: Gilead Sciences Inc. - Key news
• Exhibits151: Gilead Sciences Inc. - Key offerings
• Exhibits152: GlaxoSmithKline Plc - Overview
• Exhibits153: GlaxoSmithKline Plc - Business segments
• Exhibits154: GlaxoSmithKline Plc - Key news
• Exhibits155: GlaxoSmithKline Plc - Key offerings
• Exhibits156: GlaxoSmithKline Plc - Segment focus
• Exhibits157: Ipsen Pharma - Overview
• Exhibits158: Ipsen Pharma - Business segments
• Exhibits159: Ipsen Pharma - Key offerings
• Exhibits160: Ipsen Pharma - Segment focus
• Exhibits161: Johnson and Johnson Services Inc. - Overview
• Exhibits162: Johnson and Johnson Services Inc. - Business segments
• Exhibits163: Johnson and Johnson Services Inc. - Key news
• Exhibits164: Johnson and Johnson Services Inc. - Key offerings
• Exhibits165: Johnson and Johnson Services Inc. - Segment focus
• Exhibits166: Merck and Co. Inc. - Overview
• Exhibits167: Merck and Co. Inc. - Business segments
• Exhibits168: Merck and Co. Inc. - Key news
• Exhibits169: Merck and Co. Inc. - Key offerings
• Exhibits170: Merck and Co. Inc. - Segment focus
• Exhibits171: Novartis AG - Overview
• Exhibits172: Novartis AG - Business segments
• Exhibits173: Novartis AG - Key offerings
• Exhibits174: Novartis AG - Segment focus
• Exhibits175: Ractigen Therapeutics - Overview
• Exhibits176: Ractigen Therapeutics - Product / Service
• Exhibits177: Ractigen Therapeutics - Key offerings
• Exhibits178: Inclusions checklist
• Exhibits179: Exclusions checklist
• Exhibits180: Currency conversion rates for US$
• Exhibits181: Research methodology
• Exhibits182: Validation techniques employed for market sizing
• Exhibits183: Information sources
• Exhibits184: List of abbreviations

Technavio has been monitoring the orphan drugs market and is forecast to grow by $170.8 bn during 2022-2027, accelerating at a CAGR of 14.02% during the forecast period. Our report on the orphan drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by robust pipeline and recent drug approvals, rising incidence of rare diseases, and availability of incentives for orphan drug development.

Technavio's orphan drugs market is segmented as below:

By Distribution Channel

• Hospital pharmacy
• Specialty pharmacy
• Retail pharmacy
• Others

By Product

• Biologics
• Non-biologics

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the strategic focus on alliances, partnerships, and M&A as one of the prime reasons driving the orphan drugs market growth during the next few years. Also, the emergence of combination therapies and novel targets and rising demand for genetic tests and protein biomarkers will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the orphan drugs market covers the following areas:

• Orphan drugs market sizing
• Orphan drugs market forecast
• Orphan drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading orphan drugs market vendors that include AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, bluebird bio Inc., Bristol Myers Squibb Co., CSL Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Ractigen Therapeutics, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Vertex Pharmaceuticals Inc. Also, the orphan drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global orphan drugs market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on Global orphan drugs market 2017 - 2021 ($ billion)
• 4.2 Distributed Channel Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Distributed Channel Segment 2017 - 2021 ($ billion)
• 4.3 Product Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - Product Segment 2017 - 2021 ($ billion)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ billion)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

• 6.1 Market segments
• Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
• 6.2 Comparison by Distribution Channel
• Exhibit 32: Chart on Comparison by Distribution Channel
• Exhibit 33: Data Table on Comparison by Distribution Channel
• 6.3 Hospital pharmacy - Market size and forecast 2022-2027
• Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• 6.4 Specialty pharmacy - Market size and forecast 2022-2027
• Exhibit 38: Chart on Specialty pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 39: Data Table on Specialty pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 40: Chart on Specialty pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Specialty pharmacy - Year-over-year growth 2022-2027 (%)
• 6.5 Retail pharmacy - Market size and forecast 2022-2027
• Exhibit 42: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 43: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 44: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• 6.6 Others - Market size and forecast 2022-2027
• Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
• 6.7 Market opportunity by Distribution Channel
• Exhibit 50: Market opportunity by Distribution Channel ($ billion)
• Exhibit 51: Data Table on Market opportunity by Distribution Channel ($ billion)

7 Market Segmentation by Product

• 7.1 Market segments
• Exhibit 52: Chart on Product - Market share 2022-2027 (%)
• Exhibit 53: Data Table on Product - Market share 2022-2027 (%)
• 7.2 Comparison by Product
• Exhibit 54: Chart on Comparison by Product
• Exhibit 55: Data Table on Comparison by Product
• 7.3 Biologics - Market size and forecast 2022-2027
• Exhibit 56: Chart on Biologics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 57: Data Table on Biologics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 58: Chart on Biologics - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
• 7.4 Non-biologics - Market size and forecast 2022-2027
• Exhibit 60: Chart on Non-biologics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 61: Data Table on Non-biologics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 62: Chart on Non-biologics - Year-over-year growth 2022-2027 (%)
• Exhibit 63: Data Table on Non-biologics - Year-over-year growth 2022-2027 (%)
• 7.5 Market opportunity by Product
• Exhibit 64: Market opportunity by Product ($ billion)
• Exhibit 65: Data Table on Market opportunity by Product ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 67: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibit 68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 69: Chart on Geographic comparison
• Exhibit 70: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 UK - Market size and forecast 2022-2027
• Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)
• 9.9 Canada - Market size and forecast 2022-2027
• Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
• Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
• Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• 9.10 China - Market size and forecast 2022-2027
• Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
• 9.11 Germany - Market size and forecast 2022-2027
• Exhibit 103: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 104: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 105: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 106: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
• Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 109: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 111: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 112: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 113: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 114: Matrix on vendor position and classification
• 12.3 AbbVie Inc.
• Exhibit 115: AbbVie Inc. - Overview
• Exhibit 116: AbbVie Inc. - Product / Service
• Exhibit 117: AbbVie Inc. - Key news
• Exhibit 118: AbbVie Inc. - Key offerings
• 12.4 Alnylam Pharmaceuticals Inc.
• Exhibit 119: Alnylam Pharmaceuticals Inc. - Overview
• Exhibit 120: Alnylam Pharmaceuticals Inc. - Product / Service
• Exhibit 121: Alnylam Pharmaceuticals Inc. - Key news
• Exhibit 122: Alnylam Pharmaceuticals Inc. - Key offerings
• 12.5 Astellas Pharma Inc.
• Exhibit 123: Astellas Pharma Inc. - Overview
• Exhibit 124: Astellas Pharma Inc. - Product / Service
• Exhibit 125: Astellas Pharma Inc. - Key news
• Exhibit 126: Astellas Pharma Inc. - Key offerings
• 12.6 AstraZeneca Plc
• Exhibit 127: AstraZeneca Plc - Overview
• Exhibit 128: AstraZeneca Plc - Product / Service
• Exhibit 129: AstraZeneca Plc - Key news
• Exhibit 130: AstraZeneca Plc - Key offerings
• 12.7 bluebird bio Inc.
• Exhibit 131: bluebird bio Inc. - Overview
• Exhibit 132: bluebird bio Inc. - Product / Service
• Exhibit 133: bluebird bio Inc. - Key offerings
• 12.8 Bristol Myers Squibb Co.
• Exhibit 134: Bristol Myers Squibb Co. - Overview
• Exhibit 135: Bristol Myers Squibb Co. - Product / Service
• Exhibit 136: Bristol Myers Squibb Co. - Key news
• Exhibit 137: Bristol Myers Squibb Co. - Key offerings
• 12.9 CSL Ltd.
• Exhibit 138: CSL Ltd. - Overview
• Exhibit 139: CSL Ltd. - Business segments
• Exhibit 140: CSL Ltd. - Key news
• Exhibit 141: CSL Ltd. - Key offerings
• Exhibit 142: CSL Ltd. - Segment focus
• 12.10 F. Hoffmann La Roche Ltd.
• Exhibit 143: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 144: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 145: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 146: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 147: F. Hoffmann La Roche Ltd. - Segment focus
• 12.11 Gilead Sciences Inc.
• Exhibit 148: Gilead Sciences Inc. - Overview
• Exhibit 149: Gilead Sciences Inc. - Product / Service
• Exhibit 150: Gilead Sciences Inc. - Key news
• Exhibit 151: Gilead Sciences Inc. - Key offerings
• 12.12 GlaxoSmithKline Plc
• Exhibit 152: GlaxoSmithKline Plc - Overview
• Exhibit 153: GlaxoSmithKline Plc - Business segments
• Exhibit 154: GlaxoSmithKline Plc - Key news
• Exhibit 155: GlaxoSmithKline Plc - Key offerings
• Exhibit 156: GlaxoSmithKline Plc - Segment focus
• 12.13 Ipsen Pharma
• Exhibit 157: Ipsen Pharma - Overview
• Exhibit 158: Ipsen Pharma - Business segments
• Exhibit 159: Ipsen Pharma - Key offerings
• Exhibit 160: Ipsen Pharma - Segment focus
• 12.14 Johnson and Johnson Services Inc.
• Exhibit 161: Johnson and Johnson Services Inc. - Overview
• Exhibit 162: Johnson and Johnson Services Inc. - Business segments
• Exhibit 163: Johnson and Johnson Services Inc. - Key news
• Exhibit 164: Johnson and Johnson Services Inc. - Key offerings
• Exhibit 165: Johnson and Johnson Services Inc. - Segment focus
• 12.15 Merck and Co. Inc.
• Exhibit 166: Merck and Co. Inc. - Overview
• Exhibit 167: Merck and Co. Inc. - Business segments
• Exhibit 168: Merck and Co. Inc. - Key news
• Exhibit 169: Merck and Co. Inc. - Key offerings
• Exhibit 170: Merck and Co. Inc. - Segment focus
• 12.16 Novartis AG
• Exhibit 171: Novartis AG - Overview
• Exhibit 172: Novartis AG - Business segments
• Exhibit 173: Novartis AG - Key offerings
• Exhibit 174: Novartis AG - Segment focus
• 12.17 Ractigen Therapeutics
• Exhibit 175: Ractigen Therapeutics - Overview
• Exhibit 176: Ractigen Therapeutics - Product / Service
• Exhibit 177: Ractigen Therapeutics - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 178: Inclusions checklist
• Exhibit 179: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 180: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 181: Research methodology
• Exhibit 182: Validation techniques employed for market sizing
• Exhibit 183: Information sources
• 13.5 List of abbreviations
• Exhibit 184: List of abbreviations